Target intelligence / Profile preview

Alpha-L-arabinofuranosidase and Beta-L-arabinofuranosidase (ABF)

Target
ABF
Molecular classification
Enzyme, Glycoside hydrolase
01

Overview

Alpha-L-arabinofuranosidase (EC 3.2.1.55) and Beta-L-arabinofuranosidase (EC 3.2.1.185) are glycoside hydrolases that catalyze the hydrolysis of terminal non-reducing L-arabinofuranoside residues from various complex plant polysaccharides (UniProt, 2024). These enzymes are essential for the degradation of hemicelluloses such as arabinoxylan and arabinan, which are major components of plant cell walls (CAZy Database, 2024). While not produced by the human genome, these enzymes are widely distributed among plants, fungi, and bacteria, including the commensal bacteria of the human gut microbiome (PubMed: 28431250). In the gut, they play a vital role in the fermentation of dietary fibers, contributing to the production of short-chain fatty acids that support host health (PubMed: 31235547). From a therapeutic perspective, these enzymes are not traditional drug targets; however, they are significant in the development of prebiotics and the study of microbial ecology. They have also been investigated as potential targets for narrow-spectrum antimicrobials against pathogens that rely on these enzymes for nutrient acquisition (PubMed: 15653341). Additionally, they are utilized in industrial applications such as the production of biofuels, the clarification of fruit juices, and the improvement of animal feed digestibility. Because they are absent in human cells, they offer a unique biochemical pathway that can be exploited for selective microbial modulation without direct host toxicity.

Other names
L-arabinofuranosidaseArabinosidaseAlpha-L-arabinofuranoside arabinofuranohydrolaseBeta-L-arabinofuranoside arabinofuranohydrolase
02

Mechanism of action

These enzymes catalyze the hydrolysis of terminal non-reducing alpha-L-arabinofuranoside or beta-L-arabinofuranoside residues from arabinose-containing polysaccharides by breaking glycosidic bonds (UniProt, 2024).

03

Biological functions

Carbohydrate metabolismHemicellulose degradationPolysaccharide catabolism
04

Disease associations

InfectionGut dysbiosis
05

Safety considerations

Alteration of gut microbiome diversityGastrointestinal side effects
06

Interacting drugs

1,4-dideoxy-1,4-imino-L-arabinitol (Research tool)
07

Biomarkers

Fecal microbial compositionShort-chain fatty acid (SCFA) levels

Beyond the preview

Go deeper on Alpha-L-arabinofuranosidase and Beta-L-arabinofuranosidase (ABF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-L-arabinofuranosidase and Beta-L-arabinofuranosidase (ABF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call